Amgen (AMGN) Non Operating Income (2009 - 2026)

Amgen has reported Non Operating Income for 18 years, with the latest figure at -$73.0 million in Q2 2026.

• On a quarterly basis, Non Operating Income rose 81.47% year-over-year to -$73.0 million in Q2 2026; TTM through Jun 2026 was $1.5 billion, a 29.6% decrease from a year earlier, with the FY2025 full-year figure at $2.7 billion, up 423.91% from the prior year.
• Non Operating Income was -$73.0 million for Q2 2026 at Amgen, down from $75.0 million in the prior quarter.
• The five-year high for Non Operating Income was $2.1 billion in Q3 2025, with the low at -$782.0 million in Q4 2024.
• Average Non Operating Income over 5 years is $287.7 million, with a median of -$70.0 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income plunged 4176.92% in 2022, then soared 745.96% in 2025.
• Over 5 years, Non Operating Income stood at -$67.0 million in 2022, then soared by 700.0% to $402.0 million in 2023, then plunged by 294.53% to -$782.0 million in 2024, then gained by 29.28% to -$553.0 million in 2025, then soared by 86.8% to -$73.0 million in 2026.
• The last three Non Operating Income figures came in at -$73.0 million (Q2 2026), $75.0 million (Q1 2026), and -$553.0 million (Q4 2025), per Business Quant data.